Clinical trials: Metastasis to Brain of Primary Cancer, open to volunteers
Brain Metastasis From Advanced HER2-negative Breast Cancer
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and…
- Trial name
- NCT06839560
- Testing
- Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy, Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Brain Metastasis
Brain Metastasis Development Mechanism in BCBM Patients
This study is the experimental study for brain metastasis development mechanism in patients with breast cancer with brain metastasis
- Trial name
- NCT06330870
- Testing
- WGS/TME evaluation
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Metastatic Breast Cancer
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment…
- Trial name
- NCT06598046
- Testing
- Utidelone and capecitabine
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer (NSCLC)
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
The goal of this Phase II, multicenter, open-label, single-arm clinical trial is to evaluate the intracranial efficacy and safety of lorlatinib in adults with TKI-naïve, advanced ROS1-positive non-small cell lung cancer (NSCLC)…
- Trial name
- NCT07083687
- Testing
- Lorlatinib 100 mg
- Volunteers
- 21 people
- Sponsor
- Hunan Cancer Hospital
Breast Cancer, Brain Metastases
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
This is a multi-center, open-label, two-cohort study. The purpose of this study is to evaluate the safety, tolerability and efficacy of SHR-A1811 in the treatment of HER2-positive breast cancer with brain and leptomeningeal…
- Conditions
- Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT07177950
- Testing
- SHR-A1811, radiotherapy
- Volunteers
- 51 people
- Sponsor
- Peking University Cancer Hospital & Institute
Brain Metastases, Brain Metastases, Adult
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as…
- Conditions
- Brain Metastases, Brain Metastases, Adult, Brain Cancer
- Trial name
- FACILITATE (NCT06048094)
- Testing
- 18F fluciclovine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Baptist Health South Florida
TNBC, Brain Metastasis
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
This is a single-arm, multi-center phase II study to evaluate the safety and efficacy Sacituzumab Tirumotecan (Sac-TMT) plus bevacizumab in triple-negative breast cancer patients with brain metastases.
- Trial name
- NCT07623577
- Testing
- Sacituzumab Tirumotecan (Sac-TMT), bevacizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Glioblastoma, Brain Tumor, Primary
Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor
According to the latest national cancer statistics released by the National Cancer Center in February 2022, intracranial tumors account for about 60%-70% of the more than 3.5 million cancer patients, and the morbidity and…
- Conditions
- Glioblastoma, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT06929819
- Testing
- Intraoperative Radiation Therapy in Malignant Cerebral Tumor
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
HER2+ Metastatic Breast Cancer
Asciminib in HER2+ Breast Cancer Brain Metastases
The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.
- Trial name
- ASCENdANT (NCT07136428)
- Testing
- Asciminib and Trastuzumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Brain Metastases
IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases
This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions…
- Trial name
- IMPACT MET (NCT07569263)
- Testing
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, CD70 IHC assay
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Brain Cancer, Brain Metastases
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that…
- Conditions
- Brain Cancer, Brain Metastases, Melanoma, Lung Cancer
- Trial name
- NCT04899908
- Testing
- Stereotactic Radiation, AGuIX gadolinium-based nanoparticles
- Where
- 2 sites in United States
- Volunteers
- 134 people
- Sponsor
- Brigham and Women's Hospital
MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
This study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain…
- Conditions
- MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis
- Trial name
- NCT06582940
- Testing
- MRI-guided adaptive SRT, Conventional SRT
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
Brain Metastases, Adult, Brain Metastases
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able…
- Conditions
- Brain Metastases, Adult, Brain Metastases, Brain Cancer
- Trial name
- NCT04689048
- Testing
- 18F fluciclovine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baptist Health South Florida
Brain Tumor, Primary, Brain Tumor - Metastatic
Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors
The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the…
- Trial name
- NCT05831631
- Testing
- Circulating leukocytes immunophenotype, Tumor sampling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Pietro Mortini, MD, Prof.
SCLC,Extensive Stage, Brain Metastases
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
This study aims to evaluate the safety and efficacy of hippocampal-sparing WBRT combined with SRS as first-line treatment for SCLC patients with brain metastases.
- Trial name
- NCT06243003
- Testing
- HA-WBRT plus SBRT
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer (NSCLC), Brain Metastases
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
- Trial name
- NCT07365410
- Testing
- Furmonertinib, carboplatin, pemetrexed
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Brain Metastases, HR+ Metastatic Breast Cancer
SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
- Trial name
- NCT04923542
- Testing
- Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Breast Cancer in the Brain
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
To evaluate the efficacy and safety of pyrotinib plus capecitabine in HER2-positive breast cancer patients with active brain metastases that have failed ADCs
- Trial name
- NCT06475443
- Testing
- pyrotinib plus capecitabine
- Volunteers
- 32 people
- Sponsor
- Henan Cancer Hospital
Non Small Cell Lung Cancer
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
'1. Objective Primary objective Median Intracranial Progression-free survival(icPFS) as defined by RANO(Response Assessment in Neuro-Oncology) criteria Secondary objective Progression free survival(PFS) as defined by RECIST 1.1…
- Trial name
- ELPIS (NCT06250777)
- Testing
- Trastuzumab deruxtecan
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Yonsei University
Recurrent Medulloblastoma, Refractory Medulloblastoma
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
- Conditions
- Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
- Trial name
- NCT07698899
- Testing
- 25 mCi 177Lu- DTPA-omburtamab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center